AIM101: A Novel Cancer Therapeutic for the Treatment of Multiple Cancer Types


AIM101 will be NexImmune’s first clinical candidate. It will be tested as an active immunotherapy that will be administered directly to patients.
Because the targeted antigens are well established shared-tumor immune antigens, AIM101 has the potential to address currently unmet needs across a large multi-cancer market. 
 
If successful, this approach will represent a transforming breakthrough in the way that cancer is treated.